Immunotherapy for Treating Age-Related Macular Degeneration

NU 2007-161B 

Inventors

Arthur Neufeld*

Ai Ling Wang

Abstract

Deposition of drusen, accumulations of extracellular material, in the macula is a key factor in the etiology of Age-related Macular Degeneration (AMD). Northwestern researchers have identified compounds for the treatment and prevention of drusen. The researchers use an immunotherapeutic approach, targeting antibodies to intracellular proteins that contribute to the formation of these deposits upon becoming extracellular. The antigen/antibody response mechanism removes these proteins from the eye, decreasing the formation of drusen. This technology offers a novel therapeutic treatment for Age-related Macular Degeneration. 

Applications

• Therapy for and prevention of AMD

Advantages

• Effective induction of immune response
• Treatment at various stages of AMD, addressing etiology or existing condition

IP Status

Issued US Patent No. 9,044,419